X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement has been signed for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation.
Lead Product(s): S007-867
Therapeutic Area: Cardiology/Vascular Diseases Product Name: S007-867
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Marc Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 12, 2021
Details:
CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients.
Lead Product(s): Colchicine,Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LAXAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2021
Details:
Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufacture the drug.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lee Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 09, 2021
Details:
The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: LAXAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
